WO2005115425A1 - 発酵茶抽出物を主成分とするアディポネクチン上昇作用を有する組成物 - Google Patents
発酵茶抽出物を主成分とするアディポネクチン上昇作用を有する組成物 Download PDFInfo
- Publication number
- WO2005115425A1 WO2005115425A1 PCT/JP2004/007382 JP2004007382W WO2005115425A1 WO 2005115425 A1 WO2005115425 A1 WO 2005115425A1 JP 2004007382 W JP2004007382 W JP 2004007382W WO 2005115425 A1 WO2005115425 A1 WO 2005115425A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tea extract
- fermented tea
- adiponectin
- composition
- blood
- Prior art date
Links
- 235000019225 fermented tea Nutrition 0.000 title claims abstract description 56
- 108010076365 Adiponectin Proteins 0.000 title claims abstract description 48
- 102000011690 Adiponectin Human genes 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 title abstract description 26
- 239000002245 particle Substances 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 244000269722 Thea sinensis Species 0.000 claims description 44
- 235000006468 Thea sinensis Nutrition 0.000 claims description 44
- 235000020333 oolong tea Nutrition 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- 230000003028 elevating effect Effects 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 5
- 235000020279 black tea Nutrition 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 239000002798 polar solvent Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 44
- 239000008280 blood Substances 0.000 abstract description 44
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 40
- 230000001965 increasing effect Effects 0.000 abstract description 21
- 208000029078 coronary artery disease Diseases 0.000 abstract description 19
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 208000024891 symptom Diseases 0.000 abstract description 11
- 208000019622 heart disease Diseases 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 2
- 239000005445 natural material Substances 0.000 abstract 1
- 108091008012 small dense LDL Proteins 0.000 abstract 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 38
- 230000035622 drinking Effects 0.000 description 35
- 235000013616 tea Nutrition 0.000 description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 235000012000 cholesterol Nutrition 0.000 description 12
- 238000000605 extraction Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000008214 LDL Cholesterol Methods 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108700009884 Hypoadiponectinemia Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000007718 Stable Angina Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 1
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000057799 human ADIPOQ Human genes 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 sucrose fatty acid ester Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- composition having fermented tea extract as a main component and having adiponectin elevating action
- the present invention prevents heart disease such as diabetes and coronary artery disease, comprising a fermented tea extract having an adiponectin elevating effect in the body, particularly in blood, and an effect of expanding LDL particle size, as an active ingredient, or Compositions that ameliorate the symptoms of these diseases.
- a fermented tea extract having an adiponectin elevating effect in the body, particularly in blood, and an effect of expanding LDL particle size, as an active ingredient, or Compositions that ameliorate the symptoms of these diseases.
- adipose tissue is the largest endocrine organ in the body that secretes adipose tissue-derived endocrine factors such as plasminogen activator inhibitor 1 (PAI_1), tumor necrosis factor (TNF-H), leptin, and adiponectin.
- PAI_1 plasminogen activator inhibitor 1
- TNF-H tumor necrosis factor
- leptin leptin
- adiponectin plasminogen activator inhibitor 1
- adiponectin is a 30 kDa secreted protein that is highly expressed in adipocytes and specific to adipose tissue.
- PAI-1, TNF- ⁇ , and leptin all increase in obesity's fat accumulation, whereas adiponectin's blood levels decrease in obese individuals, and conversely, decrease in weight. Increase (for example, see Non-Patent Document 2).
- Diponectin has been shown to decrease its blood concentration with the accumulation of visceral fat, which is strongly associated with the onset of obesity complications.
- blood adiponectin levels decrease independently of the degree of obesity (for example, see Non-Patent Document 3).
- Non-patent Document 4 In diabetes, blood adiponectin levels decrease in proportion to the severity of diabetes (see, for example, Non-patent Document 4). In addition, in monkey experiments, obesity caused by overeating and exercise inactivity 2 It has been reported that hypoadiponectinemia occurs before the onset of hyperinsulinemia and diabetes, which are indicators of insulin resistance, during the onset of type 2 diabetes (for example, see Non-Patent Document 5) .
- Patent Document 1 describes an anti-inflammatory agent and a monocyte-based cell growth inhibitor that utilize the effect of adiponectin on inhibiting the proliferation of monocyte and B-cell cells.
- Patent Document 2 an agent for suppressing hepatic fibrosis due to the effect of adiponectin on promoting normal hepatocyte proliferation is described.
- administration of adiponectin exhibits an anti-inflammatory effect and an inhibitory effect on hepatic fibrosis, and improves symptoms.
- Non-Patent Document 8 It has been reported that human type 2 diabetes patients are three times as likely to have myocardial infarction as healthy subjects (for example, see Non-Patent Document 8). However, it is becoming more certain that they will develop diabetes and eventually myocardial infarction (for example, see Non-Patent Document 1).
- thiazolidine derivatives which are peroxisome proliferator-activated receptor II (PPAR) agonists, have been reported to increase blood adiponectin levels in patients with impaired glucose tolerance. Although reported (see, for example, Non-Patent Document 9), no food or composition that increases the level of adiponectin in blood that can be taken on a daily basis has not been reported so far.
- PPAR peroxisome proliferator-activated receptor II
- a high cholesterol level tends to cause coronary artery disease including angina pectoris and myocardial infarction. That is, cholesterol is transported by two lipoproteins called HDL (high-density lipoprotein) cholesterol and LDL (low-density lipoprotein) cholesterol, and HDL cholesterol is accumulated on the blood vessel wall. LDL cholesterol carries hepatic cholesterol to tissues, while cholesterol is extracted and delivered to the liver. Therefore, LDL cholesterol is called the bad cholesterol because LDL cholesterol increases cholesterol carried to every corner of the body and tends to promote coronary artery disease.
- HDL high-density lipoprotein
- LDL low-density lipoprotein
- LDL cholesterol typically 26-27 nanometers, and less than 25.5 nanometers is called small-density LDL.
- This small-density LDL is oxidized as soon as it is oxidized, and oxidized LDL foams macrophages. Therefore, an increase in small-density LDL in blood is considered to promote coronary artery disease.
- Tea is a worldwide favorite beverage, and has been involved in civilization for 2000 years. Although various effects of tea have been known since ancient times, tea drinks such as oolong tea have recently been used for various physiological functions. It has been found to have antioxidant effects (see, for example, Non-Patent Document 10), anti-obesity effects (for example, see Non-Patent Document 11), See).
- tea is divided into unfermented green tea, green tea which is an unfermented tea, and semi-fermented oolong tea and completely fermented tea, because of differences in the production method, using the same plant (Camellia sinensis) leaves.
- the components contained in each tea extract differ greatly depending on the difference in the production method and process, so that the difference in flavor is apparent even when the beverage is normally consumed.
- Patent Document 1 Japanese Patent Application No. 11-61085
- Patent Document 2 Japanese Patent Application 2001—172882
- Non-Patent Document 1 "Protein Nucleic Acid Enzyme", 2003, Vol. 47 (No. 14), p. 1896-1903
- Non-Patent Document 2 "Biochem. Biophys. Res. Commun. ,, 1999, Vol. 257, p. . 79 -83
- Non-Patent Document 3 "Circulation", 1999, 100 volumes, p. 2437-2476
- Non-Patent Document 4 "Arteriosclear Thromb Vase. Biol. ,,, 2000, Volume 20, p. 159
- Non-Patent Document 5 "Diabates ,, 2001, Vol. 50, p. 1126-1133
- Non-Patent Document 6 "Diabates ,, 2002, Vol. 51, p. 2325-2328
- Non-Patent Document 7 "Nature Med. ,,, 2000, Vol. 8, p. 731-737
- Non-Patent Document 8 "Am. J. Med.” 1998, 105 vol. (1A), p. 4S-14S
- Non-Patent Document 9 "Diabates ,,, 2001, vol. 50, p. 2094-2099
- Non-patent Document 10 "J. Agric. Food Chem.”, 1999, Vol. 47, p. 633-636
- Non-patent Document 11 "Int. J. Obes. Relat. Metabl. Disord. ,, 1999, Vol. 23, p. 98
- Non-Patent Document 12 "Biosci. Biotechnol. Biochem. ,,, 2002, Vol. 66, p. 1955-1958
- the problem to be solved by the present invention is that it is derived from natural products and has no side effects. It can be used as a safe and healthy food and drink, by increasing blood adiponectin concentration and / or increasing blood LDL particle size and lowering blood small-density LDL concentration to improve diabetes and coronary artery disease. It is an object of the present invention to provide a composition for preventing heart disease such as the above, or improving the symptoms of these diseases. Another object of the present invention is to provide a composition comprising a fermented tea extract having an adiponectin elevating effect and an LDL particle size expanding effect as an active ingredient.
- the present inventors have raised the blood adiponectin concentration and / or increased the LDL particle size and reduced the blood small-density LDL concentration to reduce diabetes and heart disease such as coronary artery disease.
- drinking fermented tea extract increased blood adiponectin levels in patients with coronary artery disease, including patients with myocardial infarction and angina pectoris, and increased LDL particle size to lower blood small-density LDL levels. I found out. On the other hand, no such effect was observed for green tea, which is unfermented tea.
- an extract of oolong tea which is a semi-fermented tea, is manufactured, and 22 patients with old myocardial infarction and stable angina pectoris are allowed to drink the oolong tea extract for one month, and the drinking of the oolong tea extract is started.
- the blood adiponectin concentration and the LDL particle size were compared with the measured values before drinking the Chiron tea extract.
- the drinking of the oolong tea extract was stopped for one month, and it was confirmed whether the effect of the oolong tea extract was obtained.
- the present invention provides a composition comprising a fermented tea extract as an active ingredient and having an adiponectin elevating action and / or an action of expanding LDL particle size. Therefore, the present invention provides a composition having an adiponectin elevating effect, comprising a fermented tea extract as an active ingredient. The present invention also provides a composition comprising a fermented tea extract as an active ingredient and having an action of expanding the LDL particle size. Further, the present invention provides a composition comprising a fermented tea extract as an active ingredient and having an adiponectin elevating action and an action of expanding LDL particle size.
- composition of the present invention may be a medicinal product used by a doctor at a hospital or the like or marketed.
- composition of the present invention may be a food or drink including a health food, a functional food, a drink and a food, or may be a composition added to these food or drink.
- fermentation in the case of fermented tea means that tea is produced without energizing heat immediately on the picked tea leaves and energizing the enzymes in the tea leaves.
- oolong tea is generally produced after the leaves of Camellia sinensis are planted (extracting), the process of exposing the tea leaves to evaporate water (wilt), the process of damaging the tea leaves and promoting fermentation (shaking blue), It is a semi-fermented tea obtained through a process of roasting and heating in a kettle (roasted blue) to stop the tea, a process of kneading the tea leaves to make it easier to extract, and a finishing burning process (? Roasting).
- complete fermented tea is generally a process of picking Camellia mmk leaves, exposing the tea leaves to evaporate moisture (wilt), a process of kneading the tea leaves strongly to promote fermentation, and a process of fermenting the tea leaves (color change).
- a tea produced through a finishing burning process ? Roasting
- Semi-fermented tea typified by oolong tea and fully fermented tea typified by black tea are used to stop fermentation by heating when the enzymes contained in tea leaves have not yet been deactivated, or to lose the enzymes by using them completely.
- fermented tea refers to tea produced by fermenting C milk ⁇ nm ⁇ leaves.
- fermented tea includes all tea produced through a fermentation process, and includes, for example, semi-fermented tea (eg, oolong tea) and completely fermented tea (eg, black tea).
- semi-fermented tea eg, oolong tea
- completely fermented tea eg, black tea
- the fermented tea extract of the present invention contains an oolong tea extract or a black tea extract. No.
- the fermented tea extract used in the composition of the present invention is obtained, for example, by extracting fermented tea with an aqueous solvent.
- the aqueous solvent used for the extraction may be water alone, or water and a lower alcohol (eg, methanol, ethanol, etc.) and Z or a polar solvent (eg,
- the ratio between the fermented tea and the extraction solvent in the extraction is not particularly limited, but the extraction solvent is 2 to 1000 times the weight of the fermented tea 1 compared to the fermented tea 1, especially considering the extraction operation and efficiency. To 100 times by weight.
- the extraction temperature is not particularly limited. It is convenient from the viewpoint of workability that the extraction temperature is within the range of the boiling point of the extraction solvent, particularly at room temperature under normal pressure.
- the extraction time is preferably in the range from 10 seconds to 24 hours.
- the fermented tea extract of the present invention may be in the form of a solution extracted with the above aqueous solvent, but is a solid obtained by drying (preferably freeze-drying) such an extraction solution. I'm sorry. Therefore, in one embodiment of the present invention, the composition having an adiponectin-elevating effect and / or having an effect of expanding LDL particle size according to the present invention comprises: fermenting tea leaves with water alone, or with water and lower alcohol and Z.
- a fermented tea extract which is a solution extracted with a mixed solvent with a polar solvent, may be contained as an active ingredient.
- the composition of the present invention having an adiponectin-elevating effect and / or having an effect of expanding the LDL particle size comprises fermenting tea leaves with water alone or with water and lower alcohol and Z.
- a fermented tea extract obtained by drying a solution extracted with a mixed solvent with a polar solvent may be contained as an active ingredient.
- the concentration of the fermented tea extract of the present invention is from 0.1% by weight to 40% by weight (Brix; solid content). Are preferably used. When taken orally, the concentrations normally used for drinking are
- the concentration is in the range of 0.1% by weight to 1% by weight, it is preferable in terms of palatability to apply the extract as it is for drinking in this concentration range. If the concentration is higher than that normally used for drinking, the bitter taste may be strongly felt when drinking as it is, so it is preferable to use excipients, freeze-dried powders, etc. or tablets or capsules as health foods and drinks. .
- a health food or drink When used as a health food or drink, for example, it can be blended in dry foods, supplements, soft drinks, mineral water, alcoholic drinks, etc., but is not limited thereto.
- the fermented tea extract of the present invention When used as a health food / drink or food additive, it may be processed as a preparation.
- the preparation include powders, tablets, pills, capsules, granules, suspensions, emulsions and the like which can be solid or liquid.
- the preparation of the present invention may contain a pharmaceutically acceptable excipient.
- diluents, flavoring agents, stabilizers, lubricants for suspending agents, binders, preservatives, disintegrating agents for tablets, and the like can be used alone or in combination.
- the fermented tea extract of the present invention When used as a health food or drink or a food additive, it is desirable to prepare or blend the fermented tea extract so that the daily intake is about 0.1 lg to 3 g. However, since the fermented tea extract of the present invention is made from tea that is consumed on a daily basis, it is highly safe without side effects even if it is consumed in excess of the above intake amount. It may be prepared or formulated for ingestion.
- the composition of the present invention is useful for increasing the concentration of adiponectin in blood and / or increasing the size of LDL particles in blood to improve the symptoms of heart diseases such as diabetes and coronary artery disease.
- the dose Z may be taken over a relatively short period of time (eg, once a month) or continuously over a long period of one month or more.
- the administration Z may be taken continuously for a long period of time to prevent the above-mentioned diseases.
- composition of the present invention administration of the composition of the present invention by Z administration, improvement of the subjective symptoms of patients with heart disease such as diabetes and coronary artery disease and improvement of the symptoms of the above-mentioned diseases by physicians It can be evaluated based on findings, absence of the above diseases, etc. For example, it can also be evaluated by measuring the concentration of adiponectin in blood and / or measuring the size of LDL particles in blood.
- the effect of increasing the blood adiponectin concentration is determined by comparing the blood adiponectin concentration before and after ingesting the fermented tea extract of the present invention.
- concentration of adiponectin in the blood is determined by measuring the plasma of the subject using an enzyme immunoassay (Adiponectin assay kit, Otsuka Pharmaceutical Co., Ltd.).
- the levels of adiponectin in the blood before and after ingestion of the fermented tea extract of the present invention are compared, and if an increase is observed, it is determined that the fermented tea extract of the present invention has an adiponectin increasing effect.
- the effect of expanding the LDL particle size in blood is determined by comparing the LDL particle size in blood before and after ingesting the fermented tea extract of the present invention.
- the size of the LDL particles in the blood is determined by densitometry (CliniScan 2, Inc.) using the electrophoresis image obtained by subjecting the serum of the subject to polyacrylamide disc electrophoresis (Lipophor, Joko Co., Ltd.). Helena Laboratory).
- the average particle size of blood LDL before and after ingestion of the fermented tea extract of the present invention is compared, and if the average particle size is increased, the LDL particle size of the fermented tea extract of the present invention is increased. It was judged that there was a spreading effect, that is, the blood low-density LDL concentration could be lowered.
- Drinking the fermented tea extract significantly increases the LDL particle size and significantly increases blood adiponectin concentration, thereby preventing heart disease such as diabetes and coronary artery disease, or reducing the symptoms of these diseases. It is extremely useful in improving.
- oolong tea is a semi-fermented tea originating in China mainly in Fujian, Guangdong, Taiwan and the like. With the launch of canned drinks in Japan as well, the simplicity of the drinks has been accepted, and it has spread rapidly in accordance with the health consciousness of consumers who prefer sugar-free drinks, and is now widely cited. Because oolong tea is a tea drink, it naturally consumes a large amount of drink daily and is regularly consumed for a long period of time.However, no adverse effects have been found, and the safety of food and drink is extremely high. . Therefore, the fermented tea extract used in the present invention has very high safety, especially in long-term continuous use, This is a fermented tea that is familiar in ordinary life and has been cited as a standard. Is also accepted without difficulty.
- Example 2 Adiponectin effect by using oolong tea
- the subjects were those who voluntarily participated in the test.
- the subjects had a history of 12 patients with old myocardial infarction and 10 patients with stable angina, with an average age of 64.3 ⁇ 7.2 years, ⁇ 23 ⁇ 4, 17 males and 5 females.
- coronary risk factors for 22 subjects were 7 in hypertension, 9 in diabetes, and 1 in hypercholesterolemia.
- Two subjects, seven obesity subjects, and five smoking subjects, each subject took the test while taking the necessary drugs during the test.
- Example 2 As a fermented tea extract, 1.5 g of the oolong tea extract obtained in Example 1 was dissolved in 1000 ml of deionized water. Blood adiponectin, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and LDL particle size after drinking for a month were measured and compared with the values before drinking. In addition, for some subjects (nine subjects), the glucose concentration and hemoglobin Ale were also measured. In addition, blood was collected after stopping drinking oolong tea extract for one month, and the effect of poaching out was also confirmed.
- Blood adiponectin was measured by enzyme immunoassay (Otsuka Pharmaceutical Co., Ltd.) using an antibody prepared using recombinant human adiponectin, and lipoprotein particle size was measured by disk electrophoresis using polyacrylamide ( JAMA, 260, 1917-1921, 1988).
- Table 2 shows the results. Blood adiponectin levels before drinking oolong tea extract 6.
- the concentration was 26 ⁇ 3.26 Ai g / ml, which was 6.88 ⁇ 3.28 / i g / ml, which was found to be significantly increased (P ⁇ 0.05). After oshout, the concentration was 6.28 ⁇ 3.28 / g / ml, which was almost the same as that before drinking oolong tea extract.
- the LDL particle size was 25.02 ⁇ 0.67nm before drinking the oolong tea extract and 25.31 ⁇ 0.60nm after drinking the oolong tea extract, indicating that the particle size was significantly increased ( ⁇ ⁇ 0.01). . After oshout, it was 25.11 ⁇ 0.70 nm, which was almost the same size as before drinking oolong tea extract.
- Total cholesterol decreased from 209 ⁇ 30 mg / dl before drinking oolong tea extract to 197 ⁇ 25 mg / dl after drinking oolong tea extract (p ⁇ 0.01). In addition, it was 200 ⁇ 29 mg / dl after pouring, and was significantly lower than before drinking oolong tea extract (p ⁇ 0.05).
- Example 2 10 g of the oolong tea extract prepared in Example 1 was mixed with 53 g of lactose and 16 g of corn starch, and the mixture was wet-granulated with a corn starch binder to obtain powders and granules.
- Example 3 The powders and granules prepared in Example 3 were mixed with sucrose fatty acid ester lg and then tableted to obtain a tablet.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/007382 WO2005115425A1 (ja) | 2004-05-28 | 2004-05-28 | 発酵茶抽出物を主成分とするアディポネクチン上昇作用を有する組成物 |
CNA2004800431717A CN1976714A (zh) | 2004-05-28 | 2004-05-28 | 以发酵茶提取物为主成分的具有脂联素上升作用的组合物 |
EP04745418A EP1752154A1 (en) | 2004-05-28 | 2004-05-28 | Composition comprising fermented tea extract as the main component and having effect of incrasing adiponectin |
AU2004320044A AU2004320044A1 (en) | 2004-05-28 | 2004-05-28 | Composition comprising fermented tea extract as the main component and having effect of elevating adiponectin level |
US11/597,555 US20080317882A1 (en) | 2004-05-28 | 2004-05-28 | Composistion Comprising Fremented tea Extract as the Main Component and Having Effect of Elevation Adiponectin Level |
CA002568547A CA2568547A1 (en) | 2004-05-28 | 2004-05-28 | Composition comprising fermented tea extract as the main component and having effect of elevating adiponectin level |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/007382 WO2005115425A1 (ja) | 2004-05-28 | 2004-05-28 | 発酵茶抽出物を主成分とするアディポネクチン上昇作用を有する組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005115425A1 true WO2005115425A1 (ja) | 2005-12-08 |
Family
ID=35450655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/007382 WO2005115425A1 (ja) | 2004-05-28 | 2004-05-28 | 発酵茶抽出物を主成分とするアディポネクチン上昇作用を有する組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080317882A1 (ja) |
EP (1) | EP1752154A1 (ja) |
CN (1) | CN1976714A (ja) |
AU (1) | AU2004320044A1 (ja) |
CA (1) | CA2568547A1 (ja) |
WO (1) | WO2005115425A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006131326A2 (en) * | 2005-06-07 | 2006-12-14 | Dsm Ip Assets B.V. | Novel use of (-)-epigallocatechin gallate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09309840A (ja) * | 1996-03-18 | 1997-12-02 | Suntory Ltd | 抗脱毛症状剤 |
-
2004
- 2004-05-28 CA CA002568547A patent/CA2568547A1/en not_active Abandoned
- 2004-05-28 US US11/597,555 patent/US20080317882A1/en not_active Abandoned
- 2004-05-28 AU AU2004320044A patent/AU2004320044A1/en not_active Abandoned
- 2004-05-28 WO PCT/JP2004/007382 patent/WO2005115425A1/ja active Application Filing
- 2004-05-28 EP EP04745418A patent/EP1752154A1/en not_active Withdrawn
- 2004-05-28 CN CNA2004800431717A patent/CN1976714A/zh active Pending
Non-Patent Citations (9)
Title |
---|
DATABASE CA [online] KURIHARA H.: "Health effect of oolong tea and the application research.", XP002997009, Database accession no. 137:337144 * |
FOOD STYLE 21, vol. 6, no. 4, 2002, pages 64 - 68 * |
HOSODA K. ET AL.: "Antihyperglycemic Effect of Oolong Tea in Type2 Diabets.", DIABETES CARE, vol. 26, no. 6, June 2003 (2003-06-01), pages 1714 - 1718, XP002997008 * |
HULTHE J. ET AL.: "Low Adiponecyte-Derived Plasma Protien Adiponectin Concentration Are Associated With the Metabolic Syndrome and Small Dense Low-Density Lipoprotein Particles.", METABOLISM CLINICAL AND EXPERIMENT, vol. 52, no. 12, 2003, pages 1612 - 1614, XP002997013 * |
KURIHARA H. ET AL.: "Inhibitory Effect of Oolong Tea on the Oxidative State of Low Density Lipoprotein (LDL)", BIOL.PHARM.BULL., vol. 26, no. 5, May 2003 (2003-05-01), pages 739 - 742, XP002997011 * |
MATSUDA S. ET AL.: "Seijin Dansei no Kessho Shishitsu ni Oyobosu Uroncha no Eikyo (Effect of Oolong tea on Plasma Lipids in Men).", ANNALS OF THE INSTITUTE OF NUTRITION SCIENCES KAGAWA NUTRITION SCIENCES KAGAWA NUTRITION UNIVERSITY., vol. 4, 1996, pages 29 - 39, XP002997010 * |
MATSUURA K. ET AL.: "ochusei Shibo Kessho no Kaizen ni Tomonai TNF-x ga Teika Adiponectin ga Josho shi, Insulin Teikosei ga Kaizen shita 2 Gata Tonyobyo no 1 Rei, (Type 2 Diabetes Mellitus Exhibiting Decreased TNF-x and Increased Adiponectin", TONYOBYO (J.JAPAN DIAB.SOC.), vol. 46, no. 12, 2003, pages 955 - 959, XP002997012 * |
NANJO F.: "Kocha no Kinosei.", NEW FOOD INDUSTRY, vol. 42, no. 5, 2000, pages 49 - 55, XP002997015 * |
SHIKAZUMI S. ET AL.: "Serum adiponection is associ ated with HDL cholesterol, triglyceride and LDL diameter in young healthy men.", NIPPON DOMYAKU KOKA GAKKAI SOKAI PROGRAM SYOROKUSHU, vol. 35, 2003, pages 160 - 54, XP002997014 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006131326A2 (en) * | 2005-06-07 | 2006-12-14 | Dsm Ip Assets B.V. | Novel use of (-)-epigallocatechin gallate |
WO2006131326A3 (en) * | 2005-06-07 | 2007-07-19 | Dsm Ip Assets Bv | Novel use of (-)-epigallocatechin gallate |
Also Published As
Publication number | Publication date |
---|---|
AU2004320044A1 (en) | 2005-12-08 |
CN1976714A (zh) | 2007-06-06 |
US20080317882A1 (en) | 2008-12-25 |
CA2568547A1 (en) | 2005-12-08 |
EP1752154A1 (en) | 2007-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005095414A1 (ja) | アディポネクチン上昇剤 | |
JP2007077139A (ja) | スダチ由来の組成物、並びに当該組成物を含有する医薬組成物、健康飲食品及びサプリメント | |
KR101632580B1 (ko) | 비만 억제 효과를 갖는 건강기능식품 및 이의 제조방법 | |
Mostafa | Effect of green tea and green tea rich with catechin on blood glucose levels, serum lipid profile and liver and kidney functions in diabetic rats | |
KR20210039961A (ko) | 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법 | |
JP2008063293A (ja) | アディポネクチン分泌促進剤、並びに該アディポネクチン分泌促進剤を含有する中性脂肪減少剤、抗肥満剤、飲食品添加剤及び機能性食品 | |
WO2007001080A1 (ja) | ビワ葉抽出物を含有する飲食品及び医薬品 | |
KR100969170B1 (ko) | 여지핵 추출물을 포함하는 지방간 또는 비만의 예방 또는 치료용 조성물 | |
KR20160141353A (ko) | 간 손상 억제 및 간 기능 보호 효과를 갖는 건강기능식품 및 이의 제조방법 | |
JP2006296414A (ja) | 改質コーヒー及びコーヒー豆の焙煎方法 | |
JP2004315379A (ja) | 発酵茶抽出物を主成分とするアディポネクチン上昇作用を有する組成物 | |
JP5991617B2 (ja) | 膵リパーゼ阻害剤の製造方法 | |
WO2005115425A1 (ja) | 発酵茶抽出物を主成分とするアディポネクチン上昇作用を有する組成物 | |
JP5719498B2 (ja) | 脂肪酸合成阻害剤 | |
KR101101808B1 (ko) | 아디픽산의 신규한 용도 | |
JP2004161644A (ja) | 膵リパーゼ阻害剤及び該阻害剤を含有する食品 | |
JP5346623B2 (ja) | Ppar活性化剤 | |
CN113197288A (zh) | 改善糖耐量和甘油三脂水平的益生菌组合物及制备方法 | |
JPWO2007111242A1 (ja) | メタボリック症候群改善剤 | |
CN111032067A (zh) | 用于治疗脂肪肝病的刺地榆提取物 | |
WO2015041235A1 (ja) | 生活習慣病治療のための食品素材の使用 | |
KR20070029207A (ko) | 발효차 추출물을 주성분으로 하는 아디포넥틴 상승 작용을갖는 조성물 | |
US20240189226A1 (en) | Pharmaceutical composition for preventing or treating obesity or non-alcoholic fatty liver containing polygalin c as active ingredient | |
KR20230047927A (ko) | 커피체리 추출물을 포함하는 대사증후군의 예방, 개선 또는 치료용 조성물 | |
TW201728331A (zh) | 麥角固醇之應用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480043171.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2568547 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004745418 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004320044 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067027356 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2004320044 Country of ref document: AU Date of ref document: 20040528 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004745418 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11597555 Country of ref document: US |